Jennifer Brown, MD, PhD, on BTK Inhibitors in CLL

By Jennifer R. Brown, MD, PhD - Last Updated: December 16, 2023

Dr. Brown, of the Dana-Farber Cancer Institute, presented updated results from the ALPINE study at the 65th American Society of Hematology Annual Meeting & Exposition.

Advertisement

The ALPINE study is a phase III, randomized trial comparing the second-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib with the first-generation BTK inhibitor ibrutinib in patients with chronic lymphocytic leukemia. Patients had a median of one prior line of therapy and were naïve to BTK inhibitor treatment.

“Last year, we presented a 24-month follow-up, which demonstrated progression-free survival (PFS) was improved by zanubrutinib compared [with] ibrutinib. This year, we update that with a median 39-month follow-up across the study,” Dr. Brown said.

According to Dr. Brown, a greater number of patients discontinued ibrutinib for both progressive disease and adverse events than those who discontinued zanubrutinib. The updated PFS data showed that zanubrutinib had a 65% landmark three-year PFS compared with 55% for ibrutinib.

“Overall, the results support the high efficacy of zanubrutinib, and it is actually the first study to show improved efficacy in a head-to-head comparison of BTK inhibitors,” Dr. Brown concluded.

Post Tags:ASHNEWS2023
Advertisement
Advertisement
Advertisement
Editorial Board